Current Position of the Molecular Therapeutic Targets for Ovarian Clear Cell Carcinoma: A Literature Review

被引：10
作者：
Amano, Tsukuru [1 ]
Chano, Tokuhiro [2 ]
Yoshino, Fumi [1 ]
Kimura, Fuminori [1 ]
Murakami, Takashi [1 ]
机构：
[1] Shiga Univ Med Sci, Dept Obstet & Gynecol, Otsu, Shiga 5202192, Japan
[2] Shiga Univ Med Sci, Dept Clin Lab Med, Seta Tsukinowa Cho, Otsu, Shiga 5202192, Japan
来源：
HEALTHCARE | 2019年 / 7卷 / 03期
关键词：
ovarian clear cell carcinoma; molecular therapeutic targets; immunotherapy; anti-PD-1; antibodies; anti-PD-L1; HEPATOCYTE NUCLEAR FACTOR-1-BETA; DISTINCT-HISTOLOGIC-TYPE; POOR-PROGNOSIS; EXPRESSION PROFILES; ARL4C EXPRESSION; PTEN EXPRESSION; GENE-EXPRESSION; PIK3CA MUTATION; CANCER; ENDOMETRIOSIS;
D O I：
10.3390/healthcare7030094
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
Ovarian clear cell carcinoma (OCCC) shows low sensitivity to conventional chemotherapy and has a poor prognosis, especially in advanced stages. Therefore, the development of innovative therapeutic strategies and precision medicine for the treatment of OCCC are important. Recently, several new molecular targets have been identified for OCCC, which can be broadly divided into four categories: (a) downstream pathways of receptor tyrosine kinases, (b) anti-oxidative stress molecules, (c) AT-rich interactive domain 1A-related chromatin remodeling errors, and (d) anti-programmed death ligand 1/programmed cell death 1 agents. Several inhibitors have been discovered for these targets, and the suppression of OCCC cells has been demonstrated both in vitro and in vivo. However, no single inhibitor has shown a sufficient effectiveness in clinical pilot studies. This review outlines recent progress regarding the molecular biological characteristics of OCCC to identify future directions for the development of precision medicine and combinatorial therapies to treat OCCC.
引用
收藏
页数：12
相关论文
共 64 条
[1]   Correlation between germline mutations in MMR genes and microsatellite instability in ovarian cancer specimens [J].
Akbari, Mohammad R. ;
Zhang, Shiyu ;
Cragun, Deborah ;
Lee, Ji-Hyun ;
Coppola, Domenico ;
McLaughlin, John ;
Risch, Harvey A. ;
Rosen, Barry ;
Shaw, Patricia ;
Sellers, Thomas A. ;
Schildkraut, Joellen ;
Narod, Steven A. ;
Pal, Tuya .
FAMILIAL CANCER, 2017, 16 (03) :351-355
[2]   Abundance of mitochondrial superoxide dismutase is a negative predictive biomarker for endometriosis-associated ovarian cancers [J].
Amano, Tsukuru ;
Chano, Tokuhiro ;
Isono, Takahiro ;
Kimura, Fuminori ;
Kushima, Ryoji ;
Murakami, Takashi .
WORLD JOURNAL OF SURGICAL ONCOLOGY, 2019, 17 (1)
[3]   ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors [J].
Berns, Katrien ;
Caumanns, Joseph J. ;
Hijmans, E. Marielle ;
Gennissen, Annemiek M. C. ;
Severson, Tesa M. ;
Evers, Bastiaan ;
Wisman, G. Bea A. ;
Meersma, Gert Jan ;
Lieftink, Cor ;
Beijersbergen, Roderick L. ;
Itamochi, Hiroaki ;
van der Zee, Ate G. J. ;
de Jong, Steven ;
Bernards, Rene .
ONCOGENE, 2018, 37 (33) :4611-4625
[4]   Potential therapeutic targets in ARID1A-mutated cancers [J].
Bitler, Benjamin G. ;
Fatkhutdinov, Nail ;
Zhang, Rugang .
EXPERT OPINION ON THERAPEUTIC TARGETS, 2015, 19 (11) :1419-1422
[5]   Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers [J].
Bitler, Benjamin G. ;
Aird, Katherine M. ;
Garipov, Azat ;
Li, Hua ;
Amatangelo, Michael ;
Kossenkov, Andrew V. ;
Schultz, David C. ;
Liu, Qin ;
Shih, Ie-Ming ;
Conejo-Garcia, Jose R. ;
Speicher, David W. ;
Zhang, Rugang .
NATURE MEDICINE, 2015, 21 (03) :231-+
[6]   Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: A phase II trial of the Gynecologic Oncology Group [J].
Bookman, MA ;
Darcy, KM ;
Clarke-Pearson, D ;
Boothby, RA ;
Horowitz, IR .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (02) :283-290
[7]   Arf-like GTPases: not so Arf-like after all [J].
Burd, CG ;
Strochlic, TI ;
Setty, SRG .
TRENDS IN CELL BIOLOGY, 2004, 14 (12) :687-694
[8]   BAF complexes facilitate decatenation of DNA by topoisomerase IIα [J].
Dykhuizen, Emily C. ;
Hargreaves, Diana C. ;
Miller, Erik L. ;
Cui, Kairong ;
Korshunov, Andrey ;
Kool, Marcel ;
Pfister, Stefan ;
Cho, Yoon-Jae ;
Zhao, Keji ;
Crabtree, Gerald R. .
NATURE, 2013, 497 (7451) :624-+
[9]   MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling [J].
Engelman, Jeffrey A. ;
Zejnullahu, Kreshnik ;
Mitsudomi, Tetsuya ;
Song, Youngchul ;
Hyland, Courtney ;
Park, Joon Oh ;
Lindeman, Neal ;
Gale, Christopher-Michael ;
Zhao, Xiaojun ;
Christensen, James ;
Kosaka, Takayuki ;
Holmes, Alison J. ;
Rogers, Andrew M. ;
Cappuzzo, Federico ;
Mok, Tony ;
Lee, Charles ;
Johnson, Bruce E. ;
Cantley, Lewis C. ;
Janne, Pasi A. .
SCIENCE, 2007, 316 (5827) :1039-1043
[10]   Targeting PI3K signalling in cancer: opportunities, challenges and limitations [J].
Engelman, Jeffrey A. .
NATURE REVIEWS CANCER, 2009, 9 (08) :550-562
1234567